Lippincott ^® NursingCenter ^®

Featured Articles

• Buy

  AML FLT3 Inhibitor Quizartinib Produces High Response Rates in Relapsed/Refractory Patients

  Robert H. Carlson

• Buy

  Beyond the Bedside: Nurses as Patient Navigators

  Linda Farling, CRNP, OCN,Rebecca Gingrich, RN, MS, OCN

• Buy

  Coalition Aims to Transform Care of Patients with Advanced Cancer

  Peggy Eastman

• Buy

  Doing More with Less in Cord Blood Transplants

  Robert H. Carlson

• Buy

  End of the Line for Bevacizumab in Breast Cancer

  Robert H. Carlson

• Buy

  Esophageal/Gastric Cancers: Second-Line Chemo Extends Survival, Improves Quality of Life

  Rabiya S. Tuma PhD

• Buy

  FDA Approves Generic Version of Doxil; Expected to Help Resolve Shortage
• Buy

  FDA Approves Stivarga for Advanced GIST
• Buy

  FDA Approves T-DM1, Now Called Kadcyla, for Late-stage Breast Cancer
• Buy

  How Do I Treat Patients with Laryngeal Cancer?

  Ezra Cohen MD

• Buy

  Ibrutinib Granted FDA ‘Breakthrough Therapy’ Designation for Two B-cell Malignancies
• Buy

  iPad Exclusive: How to Undertake Quality Improvement
• Buy

  New Data on the Smoking-Bladder Cancer Link

  Julie Derossett, RN, BAS,Sarah DiGiulio

• Buy

  Oncology's Stepped-Up Efforts to Cut Hospital Use

  Lola Butcher

• Buy

  Ovarian Cancer: Good Results with MEK Inhibitor Selumetinib in Low-Grade Serous Carcinoma

  Robert H. Carlson

• Buy

  Prostate Cancer Duration of Androgen Blockade Inconclusive for 18 vs. 36 Months

  Rabiya S. Tuma PhD

• Buy

  The 12-Hour Shift and Oncology Nurse Fatigue: The latest evidence about the harms of wearing schedules, and ongoing efforts to help nurses cope

  Sarah DiGiulio